AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31862312
Drug: Single supra-therapeutic
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single supra-therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 400/24/50 µg)
Trial: 31862312
Drug: Therapeutic inhaled
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 200/12/25 µg), twice daily for 7 consecutive days
Trial: 30690191
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with oral placebo (Group A)
Trial: 30690191
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with oral metformin (Group B)
Trial: 12968235
Drug: GIK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK therapy
Trial: 21303634
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus insulin injections once an hour
Trial: 16448552
Drug: Sulfasalazine (1.5-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (1.5-6 g daily, orally t.i.d.)
Trial: 15303786
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent with occlusion (bioceramic-coated neoprene garment)
Trial: 15303786
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent without occlusion
Trial: 9257414
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin D3 administration
Trial: 8218671
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg orally every 12 hours
Trial: 3497990
Drug: PRP-D vaccine
RxNorm normalized name: Hib (PRP-D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-D vaccine (two doses, separated by two months)
Trial: 20569170
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment with adjunctive dose of vitamin C (ChP1)
Trial: 20569170
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment alone (ChP2)
Trial: 20569170
Drug: Adjunctive vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive vitamin C
Trial: 17711908
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclophosphamide (CYC), calcineurine inhibitors (cyclosporine or tacrolimus), mycophenolate mofetil, azathioprine, rituximab
Trial: 17711908
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment regimens including high doses of cyclophosphamide (CYC) and steroids
Trial: 26708320
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 mg/day
Trial: 11379805
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 60 mg/day
Trial: 9225837
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (2 IU/m2) for 12 months
Trial: 3301500
Drug: Verapamil (V)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (V) 240 mg/die
Trial: 3301500
Drug: Chlorthalidone (C)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (C) 50 mg/die
Trial: 3301500
Drug: Verapamil (V)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (V) 240 mg/die + Chlorthalidone (C) 50 mg/die (V + C)
Trial: 28851063
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT, n = 10)
Trial: 20858400
Drug: bimatoprost/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bimatoprost/timolol fixed combination
Trial: 12562448
Drug: Lansoprazole orally
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole orally disintegrating tablet, 15 mg
Trial: 12562448
Drug: Lansoprazole orally
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole orally disintegrating tablet, 30 mg
Trial: 12562448
Drug: Intact capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact capsule formulation of lansoprazole
Trial: 8637408
Drug: Velnacrine (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine (30, 75, 150, 225 mg/day for one week)
Trial: 1350927
Drug: Acetorphan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetorphan (100 mg t.d.s.)
Trial: 6529914
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Ro 21-5521 per day
Trial: 30904178
Drug: Telmisartan/Amlodipine 80/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine 80/10 mg + Rosuvastatin 20 mg (TAR group)
Trial: 30904178
Drug: Telmisartan/Amlodipine 80/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine 80/10 mg (TA group)
Trial: 30904178
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + Rosuvastatin 20 mg (TR group)
Trial: 24184810
Drug: Simeprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks
Trial: 24184810
Drug: Simeprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (100 or 150 mg, once daily)
Trial: 22266898
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL mepivacaine 1.5%
Trial: 22266898
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL mepivacaine 1.5%
Trial: 10901509
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily)
Trial: 10901509
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (simvastatin + hormone replacement therapy)
Trial: 8622055
Drug: Alternating regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating regimen (one cycle of MOPP monthly alternated with one cycle of ABVD)
Trial: 6367362
Drug: Sulpiride (800-2800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (800-2800 mg/day, median 1600 mg/day)
Trial: 6367362
Drug: Haloperidol (6-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (6-18 mg/day, median 12 mg/day)
Trial: 31465088
Drug: mFOLFOX6 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 plus aflibercept (4 mg/kg every 2 weeks for 6 cycles, 3 months)
Trial: 23122916
Drug: VNS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VNS therapy (all doses)
Trial: 8783326
Drug: Intra-articular clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular clonidine 150 micrograms diluted in 20 ml of isotonic saline
Trial: 8783326
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg diluted in 20 ml of isotonic saline injected into the knee joint
Trial: 8783326
Drug: Intra-articular isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular isotonic saline and subcutaneous clonidine 150 micrograms
Trial: 1740587
Drug: Phenylephrine (alpha-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (alpha-adrenergic agonist)
Trial: 1740587
Drug: Beta-adrenergic agonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic agonists
Trial: 27127102
Drug: Valsartan/Amlodipine (Val/Aml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine (Val/Aml 80/5 mg) single-pill combination for 8 weeks
Trial: 23532242
Drug: Erythromycin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (400 mg, twice daily)
Trial: 20399059
Drug: Niacin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (target dose, 2000 mg/day)
Trial: 19932541
Drug: Lovastatin, 20
RxNorm normalized name: Lovastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin, 20 mg/d
Trial: 10447643
Drug: Lomefloxacin 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 0.3% eye drops twice daily (LF)
Trial: 10447643
Drug: Control antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control antibiotics (combined control group, CCG)
Trial: 8681494
Drug: Quinaprilat (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaprilat (0.5 to 1.0 mg, 1.0 to 2.5 mg, 5.0 to 10.0 mg)
Trial: 8681494
Drug: Quinaprilat (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaprilat (multiple doses every 6 hours on days 2 and 3)
Trial: 2071560
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine administered four times daily for 3 weeks
Trial: 20307823
Drug: Individualized yoga
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized yoga treatment
Trial: 2475915
Drug: Laser +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser + high-dose-rate Iridium 192 afterloading therapy
Trial: 1031798
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection tests (HOLLANDER criterion)
Trial: 1031798
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection tests (BACHRACH criterion)
Trial: 28727704
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% with dexamethasone 8 mg
Trial: 14509552
Drug: Non-antibiotic prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotic prescriptions (co-prescriptions)
Trial: 14509552
Drug: Antibiotic prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescriptions
Trial: 14509552
Drug: Mucomodifiers, steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucomodifiers, steroidal anti-inflammatory drugs, and bronchodilators
Trial: 14509552
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs and antitussives
Trial: 3544661
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate (MH) prophylaxis, 1 g three times daily
Trial: 23989910
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of flomoxef (group 1)
Trial: 23989910
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of flomoxef (five additional doses after surgery, group 2)
Trial: 21957982
Drug: Penile block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penile block (0.25% bupivacaine, 0.5 mg·kg(‐1))
Trial: 21957982
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural (0.25% bupivacaine, 0.5 ml·kg(‐1))
Trial: 20049951
Drug: 6-Mercaptopurine (6-MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-Mercaptopurine (6-MP) at 30 mg/day for 12 weeks
Trial: 20049951
Drug: 6-MP at
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-MP at 15-80 mg/day based on RBC 6-TGN, WBC count, and body weight
Trial: 10195551
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg/kg as an i.v. bolus
Trial: 10195551
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium 5 mg/kg as an i.v. bolus
Trial: 8665995
Drug: Flosulide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosulide 25 mg b.d.
Trial: 8665995
Drug: Flosulide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosulide (both doses)
Trial: 8665995
Drug: Flosulide (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosulide (repeated treatment)
Trial: 7437274
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine salicylate 1.8 g (corresponding to acetylsalicylic acid (ASA) 1.0 g)
Trial: 7437277
Drug: Dipyrone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 1.0 g
Trial: 7437274
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine salicylate (ASA)
Trial: 26626794
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (group B, n = 47)
Trial: 24105610
Drug: Dronabinol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (2.5 mg twice daily for 4 weeks)
Trial: 20577130
Drug: CPAP added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPAP added to conventional treatment (n = 38)
Trial: 20577130
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (n = 37)
Trial: 17434094
Drug: Glucose-potassium-insulin (GKI)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-potassium-insulin (GKI) infusions
Trial: 8944090
Drug: Mipragoside 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipragoside 0.5% aqueous ophthalmic gel, administered four times a day for 2 weeks after a week of placebo treatment
Trial: 8944090
Drug: Mipragoside 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipragoside 0.5% aqueous ophthalmic gel
Trial: 24919195
Drug: Low-dose protocol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose protocol (100 kVp tube voltage, 100 mAs tube current, 3.2 pitch, sinogram affirmed iterative reconstruction)
Trial: 23324248
Drug: DCE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCE plus best medical treatment (BMT)
Trial: 19925464
Drug: Tacrolimus/MMF/steroids (Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus/MMF/steroids (Control)
Trial: 17884451
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/d for 12 weeks
Trial: 10086835
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dolasetron mesylate intravenous infusion
Trial: 10086835
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dolasetron mesylate intravenous infusion
Trial: 10086835
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron mesylate intravenous infusion
Trial: 10086835
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron mesylate oral administration
Trial: 2188202
Drug: Whole-cell pertussis-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis-component diphtheria and tetanus toxoids and pertussis vaccine (DTP)
Trial: 2188202
Drug: Licensed DTP
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed DTP vaccine
Trial: 2188202
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis component DTP vaccine
Trial: 2188202
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine (in infants)
Trial: 2188202
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine (in 4- to 6-year-old children)
Trial: 16135575
Drug: Intramuscular ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ephedrine 25 mg
Trial: 7066739
Drug: Intramuscular ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ephedrine 50 mg
Trial: 7066739
Drug: Intramuscular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular saline (placebo)
Trial: 27235666
Drug: DHA supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplement >185 mg/day
Trial: 27235666
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DHA supplement)
Trial: 25820612
Drug: 3-month paliperidone
RxNorm normalized name: paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-month paliperidone palmitate (175, 263, 350, or 525 mg eq)
Trial: 21063203
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (general)
Trial: 17324670
Drug: Soy-protein-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-protein-rich diet (15 g soy protein/1,000 kcal daily)
Trial: 15279619
Drug: B-group vitamin
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-group vitamin supplementation (5 mg of folate, 5 mg of vitamin B2, 50 mg of vitamin B6, 0.4 mg of vitamin B12) for 14 days
Trial: 10939701
Drug: Intrathecal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine (500 microg in 1 ml volume)
Trial: 10939701
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml saline)
Trial: 1286502
Drug: Flumazenil (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.67 mg IV, range 0.2 to 1 mg)
Trial: 25733342
Drug: Weekly fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly fruit consumption, past weight loss experience, and weight loss self-efficacy
Trial: 19154823
Drug: 100 mouse
RxNorm normalized name: house mouse skin extract 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mouse units (MU)/mL dilution, 0.4cc/site, 4-quadrant injection
Trial: 19154823
Drug: 100 MU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 MU/mL dilution, 0.4cc/site, 4 sites along endplate band
Trial: 19154823
Drug: 20 MU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 MU/mL dilution, 2cc/site, 4-quadrant injection
Trial: 11157183
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg QID for 10 days
Trial: 9633738
Drug: Tramadol (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (210 mg/day)
Trial: 25573751
Drug: Metformin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (dosage not specified)
Trial: 25573751
Drug: Metformin pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin pharmacokinetics in GT genotype
Trial: 25573751
Drug: Metformin pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin pharmacokinetics in GG genotype
Trial: 19061721
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of autologous bone marrow mononuclear cells
Trial: 8322572
Drug: Propofol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (all doses)
Trial: 1443704
Drug: Propofol (larger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (larger doses)
Trial: 31992758
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks
Trial: 31992758
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in TG by 10 mg/dL from preconception to 28 weeks
Trial: 31992758
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks (for BMI ≥25)
Trial: 29454039
Drug: 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg selenium/d as selenium-enriched-yeast